Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 59.77 USD -3.47% Market Closed
Market Cap: 7.4B USD

Intrinsic Value

The intrinsic value of one HALO stock under the Base Case scenario is 78.96 USD. Compared to the current market price of 59.77 USD, Halozyme Therapeutics Inc is Undervalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HALO Intrinsic Value
78.96 USD
Undervaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Halozyme Therapeutics Inc

HALO
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for HALO cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Halozyme Therapeutics Inc
NASDAQ:HALO
US
Biotechnology
Market Cap
7.4B USD
IPO
Jan 30, 2003
US
Biotechnology
Market Cap
7.4B USD
IPO
Jan 30, 2003
Price
$false
EPS
$false
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about HALO?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Halozyme Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Halozyme Therapeutics Inc

Current Assets 1.1B
Cash & Short-Term Investments 596.1m
Receivables 308.5m
Other Current Assets 180.8m
Non-Current Assets 978.1m
PP&E 75m
Intangibles 818.7m
Other Non-Current Assets 84.5m
Efficiency

Free Cash Flow Analysis
Halozyme Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Halozyme Therapeutics Inc

Revenue
1B USD
Cost of Revenue
-159.4m USD
Gross Profit
855.9m USD
Operating Expenses
-304.4m USD
Operating Income
551.5m USD
Other Expenses
-107.4m USD
Net Income
444.1m USD
Fundamental Scores

HALO Profitability Score
Profitability Due Diligence

Halozyme Therapeutics Inc's profitability score is 83/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Gross Profit
83/100
Profitability
Score

Halozyme Therapeutics Inc's profitability score is 83/100. The higher the profitability score, the more profitable the company is.

HALO Solvency Score
Solvency Due Diligence

Halozyme Therapeutics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Short-Term Solvency
High Altman Z-Score
Long-Term Solvency
66/100
Solvency
Score

Halozyme Therapeutics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HALO Price Targets Summary
Halozyme Therapeutics Inc

Wall Street analysts forecast HALO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HALO is 69.11 USD with a low forecast of 55.55 USD and a high forecast of 81.9 USD.

Lowest
Price Target
55.55 USD
7% Downside
Average
Price Target
69.11 USD
16% Upside
Highest
Price Target
81.9 USD
37% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Halozyme Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for HALO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

HALO Insider Trading
Buy and sell transactions by insiders

HALO News

Other Videos
What is the Intrinsic Value of one HALO stock?

The intrinsic value of one HALO stock under the Base Case scenario is 78.96 USD.

Is HALO stock undervalued or overvalued?

Compared to the current market price of 59.77 USD, Halozyme Therapeutics Inc is Undervalued by 24%.

Back to Top